{"title":"孕激素受体状态与乳腺癌预后的关系：一项荟萃分析。","authors":"Yiming Hou, Jianrong Li, Qiong Zhang, Yingyi Fan","doi":"10.1186/s12957-025-04001-y","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Breast cancer (BC) prognosis is influenced by hormones, of which progesterone receptor (PR) status is controversial for BC prognosis, possibly related to clinical characteristics.</p><p><strong>Objective: </strong>This study was to determine the impact of PR status on BC prognosis and explore the differences across patient subgroups.</p><p><strong>Methods: </strong>PubMed, Cochrane Library, Embase, and Web of Science were searched for relevant studies until July 2024. NOS (Newcastle-Ottawa Scale) was leveraged for quality appraisal. Meta-analysis was performed using STATA15.1.</p><p><strong>Results: </strong>Thirty-five studies were included, involving 89,164 patients. PR-negative status was associated with worse overall survival compared to PR-positive status (HR 1.70, 95%CI 1.42 to 2.04; p < 0.001). Similar results were unveiled for disease-free survival (HR 1.62, 95%CI 1.23 to 2.14, p < 0.001), breast-cancer-specific survival (HR 2.45, 95% CI 1.85 to 3.23, p < 0.001), and recurrence-free survival (HR 1.47, 95% CI 1.21 to 1.79, p < 0.001). Subgroup analyses unveiled that conclusions were influenced by region, estrogen receptor (ER) status, human epidermal growth factor receptor 2 (HER2) status, menopausal status, and metastatic status.</p><p><strong>Conclusion: </strong>PR loss is associated with worse outcomes in BC, which is influenced by clinical characteristics. Especially in patients with ER + HER2- tumors, PR status may serve as an additional predictive marker.</p>","PeriodicalId":23856,"journal":{"name":"World Journal of Surgical Oncology","volume":"23 1","pages":"356"},"PeriodicalIF":2.5000,"publicationDate":"2025-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12490167/pdf/","citationCount":"0","resultStr":"{\"title\":\"Association of progesterone receptor status with breast cancer prognosis: a meta-analysis.\",\"authors\":\"Yiming Hou, Jianrong Li, Qiong Zhang, Yingyi Fan\",\"doi\":\"10.1186/s12957-025-04001-y\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Breast cancer (BC) prognosis is influenced by hormones, of which progesterone receptor (PR) status is controversial for BC prognosis, possibly related to clinical characteristics.</p><p><strong>Objective: </strong>This study was to determine the impact of PR status on BC prognosis and explore the differences across patient subgroups.</p><p><strong>Methods: </strong>PubMed, Cochrane Library, Embase, and Web of Science were searched for relevant studies until July 2024. NOS (Newcastle-Ottawa Scale) was leveraged for quality appraisal. Meta-analysis was performed using STATA15.1.</p><p><strong>Results: </strong>Thirty-five studies were included, involving 89,164 patients. PR-negative status was associated with worse overall survival compared to PR-positive status (HR 1.70, 95%CI 1.42 to 2.04; p < 0.001). Similar results were unveiled for disease-free survival (HR 1.62, 95%CI 1.23 to 2.14, p < 0.001), breast-cancer-specific survival (HR 2.45, 95% CI 1.85 to 3.23, p < 0.001), and recurrence-free survival (HR 1.47, 95% CI 1.21 to 1.79, p < 0.001). Subgroup analyses unveiled that conclusions were influenced by region, estrogen receptor (ER) status, human epidermal growth factor receptor 2 (HER2) status, menopausal status, and metastatic status.</p><p><strong>Conclusion: </strong>PR loss is associated with worse outcomes in BC, which is influenced by clinical characteristics. Especially in patients with ER + HER2- tumors, PR status may serve as an additional predictive marker.</p>\",\"PeriodicalId\":23856,\"journal\":{\"name\":\"World Journal of Surgical Oncology\",\"volume\":\"23 1\",\"pages\":\"356\"},\"PeriodicalIF\":2.5000,\"publicationDate\":\"2025-10-02\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12490167/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"World Journal of Surgical Oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1186/s12957-025-04001-y\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"World Journal of Surgical Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12957-025-04001-y","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
Association of progesterone receptor status with breast cancer prognosis: a meta-analysis.
Background: Breast cancer (BC) prognosis is influenced by hormones, of which progesterone receptor (PR) status is controversial for BC prognosis, possibly related to clinical characteristics.
Objective: This study was to determine the impact of PR status on BC prognosis and explore the differences across patient subgroups.
Methods: PubMed, Cochrane Library, Embase, and Web of Science were searched for relevant studies until July 2024. NOS (Newcastle-Ottawa Scale) was leveraged for quality appraisal. Meta-analysis was performed using STATA15.1.
Results: Thirty-five studies were included, involving 89,164 patients. PR-negative status was associated with worse overall survival compared to PR-positive status (HR 1.70, 95%CI 1.42 to 2.04; p < 0.001). Similar results were unveiled for disease-free survival (HR 1.62, 95%CI 1.23 to 2.14, p < 0.001), breast-cancer-specific survival (HR 2.45, 95% CI 1.85 to 3.23, p < 0.001), and recurrence-free survival (HR 1.47, 95% CI 1.21 to 1.79, p < 0.001). Subgroup analyses unveiled that conclusions were influenced by region, estrogen receptor (ER) status, human epidermal growth factor receptor 2 (HER2) status, menopausal status, and metastatic status.
Conclusion: PR loss is associated with worse outcomes in BC, which is influenced by clinical characteristics. Especially in patients with ER + HER2- tumors, PR status may serve as an additional predictive marker.
期刊介绍：
World Journal of Surgical Oncology publishes articles related to surgical oncology and its allied subjects, such as epidemiology, cancer research, biomarkers, prevention, pathology, radiology, cancer treatment, clinical trials, multimodality treatment and molecular biology. Emphasis is placed on original research articles. The journal also publishes significant clinical case reports, as well as balanced and timely reviews on selected topics.
Oncology is a multidisciplinary super-speciality of which surgical oncology forms an integral component, especially with solid tumors. Surgical oncologists around the world are involved in research extending from detecting the mechanisms underlying the causation of cancer, to its treatment and prevention. The role of a surgical oncologist extends across the whole continuum of care. With continued developments in diagnosis and treatment, the role of a surgical oncologist is ever-changing. Hence, World Journal of Surgical Oncology aims to keep readers abreast with latest developments that will ultimately influence the work of surgical oncologists.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
